TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03551860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TQL
Description: For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FIB
Description: The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated.
Study: NCT02557646

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P

Intervention type: DRUG
Intervention: Ribavirin
Description: Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
Study: NCT02011737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naftopidil 75mg
Study: NCT02379806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00632411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit Line Program
Description: Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit Line Program
Description: Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention.
Study: NCT03971890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance therapy
Description: The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational group
Description: The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
Study: NCT03153254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test upper limb robot assisted therapy device
Description: During 1 session of 1/2 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with new upper limb robot assisted therapy device
Description: During 2 to 5 sessions of 1/2 hour.
Study: NCT01195415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT04240925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV with sigh breaths
Description: Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NIMV
Description: Will be treated by standard NIMV with no sigh
Study: NCT02155842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity endurance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous endurance exercise
Study: NCT04208620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Cotadutide administered subcutaneously
Study: NCT03930576

Intervention type: OTHER
Intervention: Receipt of termination services outside of legal setting
Description: This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
Study: NCT02792933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air in epidural space
Description: The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline in epidural space
Description: The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
Study: NCT00913003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
Study: NCT01370174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Training Interventions
Description: Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
Study: NCT01521455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0910
Description: 250/50, BID for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 250/50, BID for 2 weeks
Study: NCT02151253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Armodafinil
Description: Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Study: NCT02485574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal lumbar interbody arthrodesis
Description: Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal lumbar interbody arthrodesis
Description: Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
Study: NCT03107325

Intervention type: OTHER
Group type: OTHER
Intervention: Modification in acquisition protocol
Description: Participants will be asked to be imaged at an additional time point.

Intervention type: DRUG
Group type: OTHER
Intervention: F-18 Fluorodeoxyglucose
Description: Participants will be asked to be imaged at an additional time point during an FDG PET study
Study: NCT00555321

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Intravenous (IV), 20 mg, Day1 and Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept More Intensive (MI)
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept More Intensive (MI)
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Less Intensive (LI)
Description: Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil (MMF)
Description: Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
Study: NCT02609750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
Study: NCT03392883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
Study: NCT03416920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellframe
Description: Wellframe mobile phone app
Study: NCT00592228

Intervention type: DEVICE
Group type: OTHER
Intervention: Cypher, Taxus or Endeavor
Description: percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group
Study: NCT00137046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study: NCT00784992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endonasal dacryocystorhinostomy
Description: The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted.
Study: NCT01066533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping and covering the exposed pulp
Description: In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping and covering the exposed pulp
Description: In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
Study: NCT01878058

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Scan
Description: Patient will receive an additional MRI scan in addition to their standard of care imaging
Study: NCT05329272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training Intervention (VRCTI)
Description: The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
Study: NCT03017651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OM3-supplement 1
Description: 1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OM3-supplement 2
Description: 1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption